Home LiteratureArticle Details
PMID: 12841382 Published · ppublish English Journal Article Review

Immunotherapy for lymphomas.

International journal of hematology ·Vol. 77 ·No. 5 ·2003-06-00 ·Pages 444-55

Timmerman JM

Abstract

A growing list of immunotherapeutic strategies is now being employed to combat lymphoid malignancies. These efforts are warranted given that B-cell lymphomas, particularly those of the common follicular subtype, are among the most "immune-responsive" of all human cancers. Although systemic cytokine therapies for B-cell malignancies have been largely disappointing to date, monoclonal antibody therapies, principally the anti-CD20 antibody rituximab, have already made enormous impact on the treatment algorithm for many B-cell lymphomas. Therapeutic vaccines targeting the tumor-specific immunoglobulin idiotype have demonstrated promising results against lymphomas in phase I/II studies and are currently being evaluated in phase III randomized trials. Additional vaccine therapies being developed include those based on dendritic cells, recombinant idiotype proteins, DNA, heat shock proteins, and gene-modified tumor cells. It is hoped that immunotherapeutic agents, used in tandem or in combination, may someday allow effective treatment of lymphoid malignancies and delay or even replace the need for conventional cytotoxic therapies.

MeSH Terms
Antibodies, Monoclonal/therapeutic use Cancer Vaccines Cytokines/therapeutic use Humans Immunotherapy/methods Immunotherapy, Adoptive/methods Lymphoma/therapy Lymphoma, B-Cell/therapy Treatment Outcome
Chemicals
Antibodies, Monoclonal Cancer Vaccines Cytokines
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Timmerman John M
Division of Hematology/Oncology, University of California, Center for Health Sciences, Los Angeles, California 90095-1678, USA. jtimmerman@mednet.ucla.edu
References (85)
85 references, click to expand
  1. Heat shock protein--peptide complexes as immunotherapy for human cancer.
    Mol Med Today. 1998 Nov;4(11):478-84 PMID: 9857367
  2. Rituximab treatment results in impaired secondary humoral immune responsiveness.
    Blood. 2002 Sep 15;100(6):2257-9 PMID: 12200395
  3. Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants.
    Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):703-8 PMID: 9892697
  4. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.
    Blood. 2002 Feb 1;99(3):754-8 PMID: 11806974
  5. The host-tumor immune conflict: from immunosuppression to resistance and destruction.
    Immunol Today. 1997 Oct;18(10):493-7 PMID: 9357142
  6. Rituximab: Mechanism of action and resistance.
    Semin Oncol. 2002 Feb;29(1S2):2-9 PMID: 28140087
  7. Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12.
    Blood. 2002 Apr 1;99(7):2512-7 PMID: 11895787
  8. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40.
    Nat Med. 1999 Jul;5(7):780-7 PMID: 10395323
  9. A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma.
    Br J Cancer. 2001 Jul 6;85(1):29-35 PMID: 11437398
  10. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity.
    Nat Biotechnol. 1999 Mar;17(3):253-8 PMID: 10096292
  11. TCR vaccines for active immunotherapy of T cell malignancies.
    J Immunol. 1997 Dec 1;159(11):5516-27 PMID: 9548492
  12. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.
    Blood. 1994 Jan 15;83(2):435-45 PMID: 7506951
  13. Fortifying B cells with CD154: an engaging tale of many hues.
    Immunology. 2000 Jul;100(3):269-80 PMID: 10929048
  14. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma.
    Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13141-6 PMID: 9789055
  15. Lysis of syngeneic tumor B cells by autoreactive cytotoxic T lymphocytes specific for a CD19 antigen-derived synthetic peptide.
    J Immunother Emphasis Tumor Immunol. 1996 Sep;19(5):346-56 PMID: 8941874
  16. A new era for cancer immunotherapy based on the genes that encode cancer antigens.
    Immunity. 1999 Mar;10(3):281-7 PMID: 10204484
  17. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help.
    Nat Med. 1999 May;5(5):548-53 PMID: 10229232
  18. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity.
    J Immunol. 1996 May 15;156(10):3858-65 PMID: 8621924
  19. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.
    Blood. 2002 May 15;99(10):3554-61 PMID: 11986207
  20. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.
    Science. 1991 Dec 13;254(5038):1643-7 PMID: 1840703
  21. Cancer vaccines.
    Nat Med. 1998 May;4(5 Suppl):525-31 PMID: 9585204
  22. The history of the development of vaccines for the treatment of lymphoma.
    Clin Lymphoma. 2000 Sep;1(2):129-39; discussion 140 PMID: 11707821
  23. Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: a therapeutic target.
    Fed Proc. 1977 Aug;36(9):2268-71 PMID: 69552
  24. The promise of nucleic acid vaccines.
    Gene Ther. 2000 Jan;7(2):89-92 PMID: 10673713
  25. Interleukin-12 in anti-tumor immunity and immunotherapy.
    Cytokine Growth Factor Rev. 2002 Apr;13(2):155-68 PMID: 11900991
  26. B cells inhibit induction of T cell-dependent tumor immunity.
    Nat Med. 1998 May;4(5):627-30 PMID: 9585241
  27. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia.
    Blood. 2000 Nov 1;96(9):2917-24 PMID: 11049967
  28. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors.
    N Engl J Med. 1992 Oct 22;327(17):1209-15 PMID: 1406793
  29. Rescue of immunoglobulin secretion from human neoplastic lymphoid cells by somatic cell hybridization.
    Proc Natl Acad Sci U S A. 1978 May;75(5):2411-5 PMID: 97669
  30. Mechanisms and therapeutic applications of immune stimulatory cpG DNA.
    Pharmacol Ther. 1999 Nov;84(2):113-20 PMID: 10596901
  31. Vaccine therapies for non-Hodgkin's lymphoma.
    Curr Treat Options Oncol. 2002 Aug;3(4):307-15 PMID: 12074767
  32. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells.
    Nat Med. 1996 Jan;2(1):52-8 PMID: 8564842
  33. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma.
    Nat Med. 1998 Nov;4(11):1281-6 PMID: 9809552
  34. Interleukin-2 treatment in lymphoma: a phase II multicenter study.
    Blood. 1994 Apr 15;83(8):2081-5 PMID: 8161779
  35. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a.
    Clin Cancer Res. 2000 Jul;6(7):2644-52 PMID: 10914705
  36. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells.
    J Clin Invest. 1998 Mar 1;101(5):1133-41 PMID: 9486984
  37. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma.
    Blood. 2002 Jan 1;99(1):67-74 PMID: 11756154
  38. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines.
    Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2268-73 PMID: 10051630
  39. CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity.
    Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5561-6 PMID: 11929985
  40. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients.
    Ann Oncol. 2000 Nov;11(11):1427-36 PMID: 11142483
  41. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
    Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3539-43 PMID: 8097319
  42. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
    Cancer Res. 2002 Oct 15;62(20):5845-52 PMID: 12384547
  43. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.
    Nat Med. 2000 Apr;6(4):443-6 PMID: 10742152
  44. CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells.
    Leukemia. 2001 Oct;15(10):1619-26 PMID: 11587221
  45. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.
    Nat Med. 1998 Mar;4(3):321-7 PMID: 9500606
  46. Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines.
    Blood. 2000 May 15;95(10):3011-9 PMID: 10807763
  47. Creating therapeutic cancer vaccines: notes from the battlefield.
    Trends Immunol. 2001 Jan;22(1):5-7 PMID: 11286676
  48. Meta-analysis to assess the efficacy of interferon-alpha in patients with follicular non-Hodgkin's lymphoma.
    J Immunother. 2001 Jan-Feb;24(1):58-65 PMID: 11211149
  49. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody.
    N Engl J Med. 1982 Mar 4;306(9):517-22 PMID: 6173751
  50. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens.
    J Immunol. 2001 Dec 1;167(11):6644-53 PMID: 11714836
  51. A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines.
    Hum Gene Ther. 1999 Aug 10;10(12):1983-91 PMID: 10466632
  52. Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1.
    J Immunol. 1987 Jan 15;138(2):628-34 PMID: 3491853
  53. Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12.
    Clin Cancer Res. 2001 Mar;7(3 Suppl):895s-901s PMID: 11300489
  54. Dendritic cell vaccines for cancer immunotherapy.
    Annu Rev Med. 1999;50:507-29 PMID: 10073291
  55. DNA fusion vaccines against B-cell tumors.
    Trends Mol Med. 2001 Dec;7(12):566-72 PMID: 11733220
  56. T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody.
    J Immunol. 2002 Mar 15;168(6):2720-8 PMID: 11884438
  57. Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells.
    J Exp Med. 2002 Jan 7;195(1):125-33 PMID: 11781371
  58. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial.
    Blood. 1997 May 1;89(9):3129-35 PMID: 9129015
  59. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits.
    J Immunol. 1987 Oct 15;139(8):2825-33 PMID: 3498771
  60. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.
    Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10972-7 PMID: 8855293
  61. Autologous and MHC class I-negative allogeneic tumor cells secreting IL-12 together cure disseminated A20 lymphoma.
    Blood. 2003 Jan 15;101(2):568-75 PMID: 12393660
  62. Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab).
    Clin Immunol. 2001 Feb;98(2):175-9 PMID: 11161973
  63. Cancer vaccines for hematologic malignancies.
    Cancer Control. 2002 Mar-Apr;9(2):138-51 PMID: 11965234
  64. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer.
    Cancer Res. 1997 Apr 15;57(8):1537-46 PMID: 9108457
  65. TCR vaccines against T cell lymphoma: QS-21 and IL-12 adjuvants induce a protective CD8+ T cell response.
    J Immunol. 1999 Feb 15;162(4):2251-8 PMID: 9973501
  66. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma.
    Blood. 2001 Sep 1;98(5):1352-7 PMID: 11520782
  67. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone.
    Blood. 1998 Aug 15;92(4):1184-90 PMID: 9694706
  68. Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells.
    Nat Med. 2002 Aug;8(8):801-7 PMID: 12101408
  69. Immunobiology of dendritic cells.
    Annu Rev Immunol. 2000;18:767-811 PMID: 10837075
  70. Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells.
    Blood. 2000 Feb 15;95(4):1342-9 PMID: 10666209
  71. Phase I study of recombinant human CD40 ligand in cancer patients.
    J Clin Oncol. 2001 Jul 1;19(13):3280-7 PMID: 11432896
  72. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma.
    Br J Haematol. 2002 Jun;117(4):828-34 PMID: 12060117
  73. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.
    Blood. 2002 Mar 1;99(5):1517-26 PMID: 11861263
  74. Active immunization against cancer with dendritic cells: the near future.
    Int J Cancer. 2001 Nov;94(4):459-73 PMID: 11745430
  75. DNA immunization induces protective immunity against B-cell lymphoma.
    Nat Med. 1996 Sep;2(9):1038-41 PMID: 8782465
  76. The natural history of initially untreated low-grade non-Hodgkin's lymphomas.
    N Engl J Med. 1984 Dec 6;311(23):1471-5 PMID: 6548796
  77. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab).
    Semin Oncol. 2002 Feb;29(1S2):81-86 PMID: 28140096
  78. Antibody-directed therapies for hematological malignancies.
    Trends Mol Med. 2002 Feb;8(2):69-76 PMID: 11815272
  79. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma.
    Nat Med. 1999 Oct;5(10):1171-7 PMID: 10502821
  80. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
    J Clin Oncol. 1998 Aug;16(8):2825-33 PMID: 9704735
  81. Vaccination with CD20 peptides induces a biologically active, specific immune response in mice.
    Blood. 2002 May 15;99(10):3748-55 PMID: 11986232
  82. Synergism between cytosine-guanine oligodeoxynucleotides and monoclonal antibody in the treatment of lymphoma.
    Semin Oncol. 2002 Feb;29(1S2):93-97 PMID: 28140098
  83. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine.
    J Immunol. 2000 May 1;164(9):4797-803 PMID: 10779787
  84. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Haematologica. 2002 Sep;87(9):989-1001 PMID: 12217812
  85. Current and ongoing clinical development of immunotherapy in B-cell malignancies. Proceedings of a conference. January 2001, Kailua-Kona, Hawaii, USA.
    Semin Oncol. 2002 Feb;29(1 Suppl 2):1-112; quiz 113-21 PMID: 11876162
Article Info
Journal
International journal of hematology
Abbr.
Int J Hematol
ISSN
0925-5710
DOI
10.1007/BF02986612
Email
jtimmerman@mednet.ucla.edu
Published
2003-06-00
Pages
444-55
Language
English
Region
Japan
NLM ID
9111627
Subset
IM
External Links
PubMed source DOI: 10.1007/BF02986612 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2